A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
The Thetis Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers
Vanda Pharmaceuticals
280 participants
Mar 27, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.
Eligibility
Inclusion Criteria2
- Body Mass Index ≥ 25 and < 40 kg/m\^2
- No serious medical problems or chronic diseases, specifically no type I or type II diabetes
Exclusion Criteria4
- Another disorder that contributes to gastrointestinal symptoms
- History of intolerance and/or hypersensitivity to NK-1 receptor antagonists
- History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
- Exposure to any investigational medication within the past 60 days
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral Capsule
Oral Capsule
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07446439